Connecting Research and Experts with Journalists

• share
• favorite_border

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

• share
• favorite_border

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.

• share
• favorite_border

As the school year winds up, thousands of Aussie kids are looking forward to the summer holidays. But hand-in hand with this freedom comes an abundance of screentime, unhealthy snacks, and a lack of routine, and it has the potential to affect children’s physical and mental health.

• share
• favorite_border

A study sheds new light on how Toxoplasma gondii parasites make the proteins they need to enter a dormant stage that allows them to escape drug treatment.

• share
• favorite_border

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

More than just a holiday gathering, this free, family-friendly event marked the culmination of a year-long appeal that raised $255,000 to provide 1,350 life-saving cancer screenings in our Borderplex community. Every dollar from event sponsorships will directly support cancer screenings and diagnostics, emphasizing the transformative impact of early detection and care.

• share
• favorite_border

The way hydrocarbon molecules interact with light can affect the production of nitrous acid in the atmosphere. In this study, researchers used an ultrafast electron camera to image the motions of hydrocarbon molecules at ultrafast, ultrasmall scales. They identified a proton transfer step followed by an out-of-plane twisting motion as key components of energy relaxation after molecules interact with light.

• share
• favorite_border

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) found that larotrectinib, an oral drug that stops cancer-cell growth, was highly effective in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS) or other solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. The study, published today in the Journal of Clinical Oncology, is the first COG trial to test precision medicine in a front-line setting across all different types of solid tumors based on a genetic biomarker rather than histology. It is poised to redefine the approach to treatment for newly diagnosed fibrosarcoma and other solid tumors with the NTRK gene fusion, potentially reducing or eliminating the need for these patients to receive chemotherapy.